By inhibiting ECM production, myofibroblast proliferation and migration, and key signaling pathways such as TGFβ and mTOR, pirfenidone holds potential as a therapeutic strategy to mitigate renal fibrosis in ADPKD. Here, MTOR is linked to autosomal dominant polycystic kidney disease.